Abstract
Resting state fMRI has been employed to identify alterations in functional connectivity within or between brain regions following acute and chronic exposure to Δ9-tetrahydrocannabinol (THC), the psychoactive component in cannabis. Most studies focused a priori on a limited number of local brain areas or circuits, without considering the impact of cannabis on whole-brain network organization. The present study attempted to identify changes in the whole-brain human functional connectome as assessed with ultra-high field (7T) resting state scans of cannabis users (N = 26) during placebo and following vaporization of cannabis. Two distinct data-driven methodologies, i.e. network-based statistics (NBS) and connICA, were used to identify changes in functional connectomes associated with acute cannabis intoxication and history of cannabis use. Both methodologies revealed a broad state of hyperconnectivity within the entire range of major brain networks in chronic cannabis users compared to occasional cannabis users, which might be reflective of an adaptive network reorganization following prolonged cannabis exposure. The connICA methodology also extracted a distinct spatial connectivity pattern of hypoconnectivity involving the dorsal attention, limbic, subcortical and cerebellum networks and of hyperconnectivity between the default mode and ventral attention network, that was associated with the feeling of subjective high during THC intoxication. Whole-brain network approaches identified spatial patterns in functional brain connectomes that distinguished acute from chronic cannabis use, and offer an important utility for probing the interplay between short and long-term alterations in functional brain dynamics when progressing from occasional to chronic use of cannabis.
Subject terms: Cognitive neuroscience, Human behaviour
Introduction
The endocannabinoid system has been implicated to play a modulatory role in cognition and motor function, neuroprotection, nociception, synaptic plasticity and inflammation1. Cannabinoid type 1 (CB1) receptors are widely expressed in the brain at presynaptic terminals that are activated by endocannabinoids, a group of retrograde neurotransmitters that include anandamide and 2-arachidonoylglycerol2. Activation of CB1 receptors leads to suppression of glutamate and GABA release from the presynaptic terminal and modulates a wider range of neurotransmitter circuits of which they are part3,4. CB1 receptor activation is also thought to be responsible for the disruptive effects on human brain function, cognition and psychomotor performance caused by exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the psychoactive ingredient of cannabis5–12. A number of human studies have confirmed that psychoactive and physiological effects of cannabis can be successfully blocked or attenuated by the coadministration of a CB1 antagonist13–16.
In addition to the acute psychoactive effects of cannabis, studies have also demonstrated residual cognitive deficits in chronic cannabis users17–19. Typically, such deficits decrease during abstinence and do not persist beyond 4–5 weeks17,20. Likewise, studies have shown that cortical CB1 receptors become downregulated with years of cannabis use, but quickly start to recover within days and return to control levels within 4 weeks of abstinence21–23. These findings suggest that changes in CB1 receptor signaling contribute to the development of cognitive deficits resulting from chronic exposure to cannabis and that recoveries of CB1 receptors and cognitive deficits observed during cannabis abstinence are related24.
Recent advances in functional magnetic resonance imaging (fMRI) have allowed researchers to investigate neuronal-related temporal fluctuations in the activity of different areas in the brain. The study of the pairwise correlated/anti-correlated activity between different brain regions has become popularly known in the research community as “functional connectivity”25. Functional connectivity measures have been employed to identify brain areas that underlie acute and chronic cannabis effects on cognitive function. Overall, these analyses have shown that acute THC intoxication causes reductions in functional connectivity within the mesocorticolimbic circuit and the salience network, and that these changes are associated with decrements in cognitive function or increments in psychotomimetic symptoms10,11,26–30. Chronic use of cannabis has also been associated with a range of functional connectivity alterations that can be measured during abstinence. Hypoconnectivity in corticostriatal circuits was associated with anhedonia31,32, whereas increased functional connectivity in the posterior cingulate cortex alongside reduced functional connectivity in the hippocampus was associated with memory impairment in chronic cannabis users as compared to controls33. Chronic cannabis users also displayed increased functional connectivity between frontal brain areas and subcortical regions34,35 that have been associated to impulsive behavior35 and mood36. Likewise subcortical hyperconnectivity has been reported in cannabis dependence37.
Most functional connectivity studies in cannabis users focused a priori on a limited number of local brain areas to define acute and residual effects of THC on brain function38. Only one study so far has attempted to define patterns of whole-brain functional connectivity within and between the entire range of available brain areas to characterize cannabis induced states39. That study revealed an association between cannabis intoxication and a specific pattern of functional connectivity alterations within and between auditory and somato-motor cortices that were anti-correlated to alterations in subcortical structures and the cerebellum. The relevance of looking at the entire human functional connectome is that it might allow delineation of comprehensive patterns of functional connectivity in response to acute as well as chronic exposure to cannabis. Recent advances in functional neuroimaging have provided new tools to measure these connections in disease states, e.g. neurological disorders and alcohol abuse40–42, by studying the brain as a functional network (also called “functional connectome” or “functional connectivity matrix”) and by extracting connectivity patterns relevant to the disease at hand43. Here we hypothesized that such patterns of connectivity might fluctuate as a function of cannabis use history and transiently change during cannabis exposure. In turn, this might serve as important markers of brain function, particularly when their variability is associated with alterations in cognitive and behavioral variables that affect real-world functions of cannabis users.
The present study therefore attempted to identify changes in the whole-brain human functional connectome of cannabis users that are attributable to acute cannabis intoxication (comparing active cannabis condition vs placebo) and to chronic use of cannabis (comparing occasional vs chronic users). We used two distinct data-driven methodologies to identify changes in functional connectomes. The first, Network-Based Statistics (NBS), is a common procedure to make statistical inferences on functional connectomes44. The second, connICA45, uses independent component analysis in the connectivity domain to extract patterns of connectivity that are associated with clinical characteristics such as, in the case of this work, cannabis use history and level of cannabis intoxication as rated on scales of subjective high. Both data-driven approaches can be considered complementary. NBS provides a global estimate of whole-brain differences between occasional and chronic cannabis users and between the intoxicated and non-intoxicate state, whereas connICA potentially allows associating such global patterns to specific clinical outcome measures that are collected in parallel to brain imaging measures. We expected that this functional connectome-based investigation would offer unique insights into the alterations of human brain networks’ connectivity following acute and chronic cannabis use.
Methods
Participants, design and procedures
Participants were recruited through advertisements around Maastricht University. Inclusion criteria were: age, 18–40 years; occasional cannabis use for the occasional group, ranging between 1 time a month and 3 times a week for the past year; chronic cannabis use for the chronic group, using at least 4 times a week for the past year; body mass index between 18 and 28 kg/m2; and written informed consent. Exclusion criteria were: history of drug abuse (other than the use of cannabis) or addiction; pregnancy or lactation; health issues including hypertension (diastolic > 90 and systolic > 140), cardiac dysfunction, and liver dysfunction; current or history of endocrine, neurological, psychiatric disorders; use of psychotropic medication; previous experience of serious side effects to cannabis; and MRI contraindications. Before inclusion, subjects were screened and examined by a study physician, who checked for general health, conducted a resting ECG, and took blood and urine samples in which hematology, clinical chemistry, urine, and virology analyses were conducted. Participant demographic data can be found in Table S1. Overall, demographics did not differ between groups, except for their frequency of cannabis use.
The study was conducted according to a double‐blind, placebo‐controlled, mixed cross‐over design in cannabis users (N = 26). Each participant received cannabis placebo and cannabis (300 μg/kg THC) on separate days, separated by a minimum wash‐out period of 7 days. Medical cannabis (Bedrobinol; 13.5% THC) was obtained from Bedrocan, the Netherlands. Treatment orders were randomly assigned to participants. Cannabis and cannabis placebo were administered through a Volcano vaporizer (Storz & Bickel Volcano ®, Tuttlingen, Germany), with participants inhaling equal amounts of each while lying in the MRI scanner. The treatments were vaporized at 225 °C and the vapor was stored in a polythene bag equipped with a mouthpiece. Participants were instructed to place the mouthpiece to their lips, inhale deeply for 4 s, hold their breath for 10 s, and then exhale. Participants repeated this procedure until the balloon was empty. Participants were instructed to inhale the entire volume of the balloon within 5 min. Participants received two resting state scans at 15 min and 36 min after inhalation. Resting state scans were preceded by a psychomotor vigilance task and the collection of a blood sample and were directly followed by a rating of subjective high. Outcome parameters were averaged across successive measurements to yield a single value per individual in each treatment condition to serve as input for the connectome analysis. The current study was registered in the Netherlands trial register (NTR4897, first date of registration 7/11/2014). A previous analysis of THC effects on seed-based functional connectivity within the mesocorticolimbic circuit employing the same data set has been published elsewhere11.
Participants received a training day prior to the treatment conditions to become familiarized with the study procedures. Participants in the occasional users group (N = 12) were instructed to refrain from drug use, including cannabis, (≥ 7 days) and alcohol (≥ 24 h) prior to their testing day; whereas participants in the chronic group (N = 14) were given the same instructions, however were allowed to use cannabis up until 24 h prior to their testing day. Absence of drug and alcohol was assessed via a urine drug screen and a breath alcohol screen at the start of a test day. A pregnancy test was given if participants were female. If all tests were found to be negative (except for cannabis in the chronic group), participants were allowed to proceed.
The study was conducted according to the code of ethics on human experimentation established by the declaration of Helsinki (1964) and amended in Fortaleza (Brazil, October 2013) and was approved by the Academic Hospital and University's Medical Ethics committee (Medical ethical review board Academic Hospital Maastricht/ Maastricht University. All participants gave their written informed consent. A permit for obtaining, storing, and administering cannabis was obtained from the Dutch Drug Enforcement Administration.
Subjective and behavioral measures
Sustained attention was assessed via the psychomotor vigilance task (PVT), a 5-min reaction‐time task that measures the speed with which participants responds to a visual stimulus46. The primary outcome measure of the task is the number of attentional lapses (reaction time > 500 ms). Participants also rated their subjective high on visual analog scales (10 cm) on two consecutive time points after treatment administration, on a scale between 0 (not high at all) and 10 (extremely high). Both measures were conducted by the participants while in the scanner.
Pharmacokinetic measures
Blood samples (8 mL) to determine cannabinoid concentrations (THC and metabolites OH‐THC and THC‐COOH) were taken at baseline and prior to resting state measures and analyzed according to a standardized procedure47.
Resting state functional connectivity
All participants underwent a resting state functional MRI. Images were acquired on a MAGNETOM 7T MR scanner. A total of 258 whole‐brain EPI volumes were acquired at rest (TR = 1400 ms; TE = 21 ms; flip angle = 60°; oblique acquisition orientation; interleaved slice acquisition; 72 slices; slice thickness = 1.5 mm; voxel size = 1.5 × 1.5 × 1.5 mm). During scanning, participants were shown a black cross on a white background and were instructed to focus on the cross while attempting to clear their mind.
fMRI data were processed with an in-house developed pipeline based on Matlab and FSL, using state-of-the-art guidelines40,48,49. These steps included: BOLD volume unwarping (FSL apply topup), slice timing correction (FSL slicetimer), realignment (FSL mcflirt), normalization to mode 1000, demeaning and linear detrending (Matlab detrend), regression (Matlab regress) of 18 signals: 3 translations, 3 rotations, and 3 tissue-based regressors (mean signal of whole-brain, white matter (WM) and cerebrospinal fluid (CSF)), as well as 9 corresponding derivatives (backwards difference; Matlab). We also kept track of the fMRI volumes that were highly influenced by head motion, by using three different metrics: 1) Frame Displacement (FD, in mm); 2) DVARS (D referring to temporal derivative of BOLD time courses, VARS referring to root mean square variance over voxels) (Power et al. 2014); 3) SD (standard deviation of the BOLD signal within brain voxels at every time-point). The FD and DVARS vectors (obtained with fsl motion outliers) were used to detect outlier BOLD volumes with FD > 0.3 mm and standardized DVARS > 1.7. The SD vector obtained with Matlab was used to detect outlier BOLD volumes higher than 75 percentile + 1.5 of the interquartile range per FSL recommendation50. A bandpass first-order Butterworth filter [0.009 Hz, 0.08 Hz] was applied to all BOLD time- series at the voxel level (Matlab butter and filtfilt). As a final denoising step, the first three principal components of the BOLD signal in the WM and CSF tissue were regressed out of the gray matter (GM) signal (Matlab, pca and regress) at the voxel level. We did not perform scrubbing of volume artifacts, but used this information as a confounder in our multilinear regression analysis instead. Functional connectomes obtained with and without scrubbing were highly similar (average Pearson’s r = 0.98) and the number of volume artifacts did not significantly vary between groups or conditions (double-sided t-tests not significant).
A whole-brain data-driven functional parcellation based on 278 regions51, was projected into each subject's T1 space (FSL flirt 6dof and FSL flirt 12dof) and then into native EPI space of each subject. The voxelwise BOLD signals were averaged into the corresponding Shen brain regions, and then functional connectomes were computed as Pearson’s correlation between time series of all region pairs. Finally, the resulting functional connectomes (278 cortical and subcortical nodes) were ordered according to seven cortical resting state networks (RSNs) as proposed by Yeo et al.52. These included the visual (VIS), somatomotor (SM), dorsal attention (DA), ventral attention (VA), limbic (L), frontoparietal (FP) and the default mode network (DMN). For completeness, we added two more networks: one composed of the subcortical and one for the cerebellar regions.
We explored functional connectome changes in a population of cannabis users, using two different methodologies. The first, network-based statistics (NBS), is a connectome-wide analysis where hypothesis testing at each and every element of the connectivity matrix is performed. The second, connectivity independent component analysis (connICA), extracts independent subsystems of connectivity from the individual functional connectomes. These subsystems can then be associated with behavioral and demographic scores or scores related to treatment and cannabis use history.
Network based statistics on functional connectomes of occasional and chronic users
The network-based statistic (NBS) is a popular network-specific approach to control the family-wise error rate (FWER) when performing mass univariate testing on all connections in a functional or structural connectome44, between two or more groups (e.g., in the case of this work, between occasional and chronic users). The NBS is used in settings where each connection is associated with a test statistic and corresponding p-value, and the goal is to identify groups of connections showing a significant effect while controlling the FWER. The approach is somewhat analogous to cluster-based approaches developed for performing inference on statistical parametric maps in human neuroimaging53,54. Instead of identifying clusters of voxels in physical space, the NBS identifies connected subnetworks in topological space. The size of a subnetwork is most typically measured by the number of edges that it comprises. A summary description of the NBS workflow is given in Fig. 1A1–4.
Briefly, NBS independently computed a univariate test statistic (e.g. t-statistic) between the groups for each and every connection55. The result is a matrix of test statistic values with the same dimensions as the connectome. We then threshold the test statistic matrix to keep only the significant edges. This thresholded matrix is then connected to components, that is subnetworks of edges showing a common statistical effect of interest (Fig. 1A2). The size of each component is stored. The size of a connected component can be measured as the number of edges it comprises. After the sizes of the observed components are computed, permutation testing is used to estimate a corrected p-value for the size of each observed component, by randomly shuffling the labels assigned to each network so that the “random” groups comprise a mixture of actual occasional and chronic cannabis users. The analysis is then repeated and the size of the largest component is stored. We repeat this procedure many times to generate an empirical null distribution of maximal component size. The corrected p-value for a component of size m is then given by the proportion of permutations for which the largest component is equal to or greater in size than m (Fig. 1A3).
Here we used NBS to investigate whole-brain connectivity changes in functional connectomes of chronic and occasional users groups, during the placebo and the THC condition independently. In order to detect mean differences between functional connectome edges (i.e. connections between the nodes of the connectome), we used double-sided t-test (thresholded at p < 0.01, i.e. T score = 3.1). The cutoff alpha for the giant component size was set to 0.05. Nodal degree, an indicator of a nodal contribution to a network, was then computed by summing the edges over the columns of the thresholded binary matrix.
Connectivity independent component analysis (connICA) on functional connectomes of occasional and chronic cannabis users
ConnICA is a novel data-driven methodology that applies independent component analysis40 to extract independent connectivity patterns from individual functional connectomes. Output of connICA includes: i) an “FC-component” representing an independent pattern of functional connectivity present across participants that can be associated with a clinical or demographical variable, and ii) each participant’s contributory weight, quantifying the (signed) component strength or prominence in each individual FC matrix. A summary description of the connICA workflow is given in Fig. 1B1–4.
After the initial NBS analysis where we aimed at looking into widespread changes in chronic and occasional users’ functional connectomes, we next applied connICA to zoom into the independent “components of interest” that significantly differentiated chronic and occasional users, as well as those that were associated with the acute intoxication effect of THC. Note that in this case we used all the functional connectomes from the two groups and the two conditions, to maintain the “blind data-driven” spirit of the connICA framework.
Given the non-deterministic nature of the ICA decomposition into components56,57, multiple ICA runs are required to select the most robust outcomes40,56. As in previous work, we accounted for this by evaluating the robustness of the components (“FC-traits” in40) over 100 FastICA runs. The FC-component was considered robust when it appeared in at least 75% of the runs, as defined by a correlation of 0.75 or higher across runs40. Before running the connICA algorithm, we applied Principal Component Analysis58 to perform noise filtering and dimensionality reduction, as recommended by work in machine learning59 and neuroimaging communities60,61. After this PCA-based preprocessing, we estimated the number of independent components40,62. The two parameters of percent retained variance from PCA and number of independent components were broadly explored to find the optimal combination. For each block, we examined percent variance retained after PCA in the range [75%, 100%], in steps of 5%. Similarly, we evaluated the number of ICA components in the range [5, 25], in steps of 1. Considering our a-priori hypothesis, we aimed for the range of parameters where we had the greatest number of robust components, while preserving most of the information from the data (minimal PCA reduction). As depicted in Fig. S1, the optimal choice of these two parameters was 95% retained variance in PCA and 20 independent components.
After connICA extraction of the most robust connectivity patterns from the dataset, we performed a multi-way analysis of variance model (MATLAB anovan), in order to account for the interactions between the different factors, including the repeated measures (i.e. participants' connectomes appearing repeatedly, in different conditions) effects. The predictors included in the ANOVA model were: Drug condition (THC or placebo); cannabis user group (occasional or chronic cannabis users), gender, age, rating of subjective high and number of lapses of attention as assessed in the psychomotor vigilance task.
Finally, we evaluated and reported the connICA components where the Anova model showed significant associations for the predictors of interest, after Bonferroni correction for multiple comparisons across the number of components tested (threshold was set to p < 0.01, Bonferroni corrected). Nodal strength, an indicator of a nodal contribution to a network, was computed by summing the edges over the columns of the connICA component.
Statistics on subjective and behavioral measures
A mixed‐model analysis was performed consisting of the within‐subject factors treatment (THC and placebo) and the between‐subject factor of group (occasional or chronic) on mean subjective high ratings and number of attentional lapses averaged across two successive time points. The alpha criterion level of significance was set at p = 0.05.
Results
Subjective and behavioral data
Mixed‐model analyses of variance (ANOVA) yielded a significant main effect of Treatment on ratings of subjective high [F(1,23) = 40.26, p = < 0.001, ηp2 = 0.641] and the number of lapses of attention [F(1,23) = 4.71, p = 0.041 ηp2 = 0.169], indicating that subjective high and lapses of attention were higher in the THC condition as compared to the placebo condition. Separate contrasts revealed that THC increased lapses of attention primarily in occasional users [F(1,12) = 5.39, p = 0.039, ηp2 = 0.310], but not in chronic users. The number of lapses of attention were also significantly higher in occasional users as compared to chronic cannabis users [F(1,23) = 9.21, p = 0.006, ηp2 = 0.238]. Mean (SE) subjective ratings of high and lapses of attention are given in Table S2.
THC concentrations in serum
Mean (SE) concentrations of THC, 11‐OH‐THC, and THC‐COOH in serum are given in Table S3. As expected from previous experience63, THC [F(2,32) = 6.29, p = 0.023] and THC-COOH [F(2,34) = 6.29, p = 0.031] levels were higher in chronic users as compared to occasional users even though they received the same dose.
Network based statistics
We performed NBS T-statistic between the two cannabis user groups, when they were in the placebo condition and while they were under the influence of THC (Fig. 2). Interestingly, NBS showed a significant broad difference in the functional connectome between the 2 user groups while under the influence of THC (T-matrix thresholded at T Score of 3.1, which equals p < 0.01, Fig. 2A–D). The functional connectome revealed (for T-test chronic > occasional) increments in functional connectivity within most Yeo-Networks (Fig. 2B–D). T-tests comparing occasional > chronic mainly showed significant changes in network connectivity between DMN and dorsal and ventral attentional networks (Fig. 2B–D). Group differences were less apparent during the placebo condition. Only the T-test chronic > occasional revealed a significant difference in the sensory-motor network. NBS did not reveal any significant differences when comparing THC vs placebo conditions in each of the cannabis user groups (see Fig. S2).
ConnICA
ConnICA allowed us to identify spatial functional connectome patterns that were related to chronic use of cannabis and to the acute state of THC intoxication. ConnICA extracted two components of interest. The first was associated with differences between the cannabis user groups across treatment conditions (Fig. 3). The second was associated with differences in subjective high during cannabis and placebo, across the two cannabis user groups (Fig. 4). The first component identified greater functional connectivity in chronic cannabis users as compared to occasional cannabis users in all networks (anova p < 0.01, Bonferroni corrected for multiple comparisons across connICA components). This finding appears broadly in line with the between cannabis user group differences that was obtained with NBS. The second component identified a functional connectivity pattern that was associated with the subjective state of cannabis intoxication as rated on visual analog scales of subjective high (anova p < 0.01, Bonferroni corrected for multiple comparisons across connICA components). The pattern consisted of an increase in functional connectivity between the default mode network and the ventral attentional network, and decreased functional connectivity between the subcortical network and the dorsal attentional network and between the cerebellum and the limbic network. Age and gender were not associated with a connICA pattern. A functional connectivity pattern associated with attentional performance did not survive the correction for multiple comparisons.
Discussion
The present study aimed to determine the effects of acute and chronic cannabis use on the whole brain connectome using two previously established methodologies, i.e. NBS and connICA, which provided consistent and complementary results. Both NBS and connICA revealed strong increments in functional connectivity within the major brain networks in chronic cannabis users as compared to occasional users, suggesting a state of hyperconnectivity. Likewise, both methodologies showed that increments within network functional connectivity in chronic cannabis users were paralleled by decrements in connectivity between networks. The impact of cannabis use history on the human connectome appeared more prominent when using the connICA methodology that allows extraction of spatial patterns of connectivity associated with clinical characteristics. Apart from a state of hyperconnectivity in chronic cannabis users, the connICA methodology also extracted a distinct spatial connectivity pattern associated with the feeling of subjective high during cannabis intoxication across both users groups.
Acute cannabis intoxication produced a select, spatial pattern in functional connectivity that was strongly associated with the feeling of subjective high in both user groups. Most prominent were decrements in functional connectivity between the subcortical and the dorsal attention network, and between the limbic and cerebellar networks that suggest a reduction of top-down attention control64 and motor coordination65 during cannabis intoxication. These findings of reduced connectivity are largely in line with a series of studies that predominantly reported hypoconnectivity within brain circuits as a primary response during cannabis intoxication10,11,27. A parallel increment in functional connectivity however was apparent between the default mode network and the ventral attention network. The ventral attention network is assumed to be involved in stimulus-driven shifts of attention64 and its increased connectivity with the self-centered default mode network suggest an increased internalization of attention directed at monitoring of mind wandering or spontaneous cognition66 during cannabis intoxication. As such, the spatial functional connectivity pattern identified by connICA reflects some of the core elements of cannabis intoxication including the feeling of subjective high and alterations in attentional and motor function67.
NBS revealed hyperconnectivity within a number of brain networks of chronic cannabis users. ConnICA subsequently identified hyperconnectivity within all brain networks as a significant pattern that distinguished chronic cannabis users from occasional cannabis users. In addition, moderate increments in functional connectivity in chronic cannabis users were also observed between a select number of networks: i.e. between the limbic network and the DMN and subcortical brain areas, and between attentional networks and the somatomotor network. This broad pattern of hyperconnectivity was also paralleled by moderate reductions of functional connectivity between remaining network edges. The prime finding of hyperconnectivity across the whole brain connectome of chronic cannabis users adds to findings of previous imaging studies showing increased functional connectivity in subcortical and frontal regions33,37,68 or between those regions34–36. The present study, however, suggests that functional hyperconnectivity in chronic cannabis users is not restricted to local brain circuits but can be observed across the entire whole brain connectome.
The widespread pattern of hyperconnectivity in the human connectome of chronic cannabis users can be interpreted in various ways. It may indicate a general downregulation of CB1 receptors that are expressed across the entire central nervous system69. A number of studies have shown a global reduction in CB1 receptor availability of 10–20% across the brain of chronic cannabis users21–23 that might be expected to produce an operational disruption in neural signaling within the neurotransmitter circuits in which they are expressed3,4. Previous studies have suggested that hyperconnectivity observed in resting state fMRI is a common response to neurological disruption that may be differentially observable across the entire brain70,71. In the context of stimulant drug abuse, development of hyperconnectivity within brain circuits has also been related to countervailing resilience systems implicated in behavioral regulation and compensation72. The finding that acute (i.e. hypoconnectivity) and chronic effects (hyperconnectivity) of cannabis on brain circuits are largely opposite may support the notion that chronic effects produced by cannabis might reflect a compensatory response of the brain to repeated cannabis use and thus stimulations of CB1 receptors. That also seems to be in line with the finding that chronic users of cannabis can develop (partial) tolerance to acutely impairing effects of cannabis, presumably as a consequence of adaptive CB1 receptor downregulation12.
Interestingly, none of the spatial patterns that were identified by connICA were associated with attentional performance differences between cannabis user groups or between treatments even though these were evident from performance data. Effects sizes of differences in attentional performance however were relatively small and, in case of a treatment effect, limited to occasional users. This may have hindered a clear-cut attribution of attentional changes to a functional connectivity pattern across the cannabis user groups, particularly after corrections for multiple comparisons. Alternatively, changes in attentional performance may also be driven by local changes in a confined brain circuit that may go undetected in a spatial analysis of whole-brain network patterns. Previous analyses have indeed linked THC induced impairment of attention to a reduction in functional connectivity within (sub)cortical areas of the reward circuit of occasional cannabis users10, but not in chronic cannabis users11. In both cases, seed-based connectivity analyses were used to test the particular hypothesis that THC-induced increment in dopamine release to the nucleus accumbens would alter its connectivity with neural structures in the reward circuit. Such lower-level, circuit-specific changes may be harder to identify with higher-level aggregation methods as employed in the present study.
Overall, the present study suggests an important utility for whole-brain network approaches in the identification and separation of acute and chronic effects of cannabis on the functional brain connectome. Incorporation of cross-network dynamics might identify neurobiological features or phenotype characteristics of impaired and adaptive behaviors that might arise during acute and chronic use of cannabis. Such models might provide unique insights into the emergence and maturation of distinct functional networks in users that progress from acute to chronic cannabis use, and into temporal alterations in network dynamics that underlie the development of pathological states73, e.g. cannabis use disorder or cannabis-induced psychosis, in a subset of users. In general, approaches that focus on large-scale brain organization or distributed brain circuits are well equipped to capture the complexity of brain function74 and subsequently may also be best suited to assess alteration in functional brain dynamics following cannabis use.
This study does not come without limitations. The sample size of the current study might have been too small to detect any association between THC induced functional connectivity patterns and clinical outcome measures, such as attentional performance as discussed above. It would therefore be advisable to repeat the current analyses in a larger sample size. Furthermore, we have chosen the Yeo atlas for establishing the whole brain functional connectome, which poses limits to the number and size of brain network parcellations that were considered. Alternative brain atlases are available that provide a larger number of functional network parcellations and increased functional specificity that would allow a more detailed analysis of local functional networks, particularly in subcortical areas.
In conclusion, we have shown with two separate methodologies that whole-brain functional connectomes can distinguish occasional from chronic cannabis users and identify acute cannabis intoxication, linking brain network dynamics with cannabis-induced long and short-term changes. This work is relevant for probing the neurobiological basis of behavioral function and dysfunction related to cannabis use, and its associated brain network dynamics, as well as to substance use in general.
Supplementary Information
Author contributions
J.R., E.T. and N.M. designed the study, N.M. collected data, N.M. and E.A. performed fMRI analyses, N.M., E.A. and J.R. evaluated fMRI data, S.T. analyzed PK data, J.R. and E.A. wrote the main manuscript text and all authors reviewed the manuscript.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
J. G. Ramaekers, Email: j.ramaekers@maastrichtuniversity.nl
E. Amico, Email: enrico.amico@epfl.ch
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-022-06509-9.
References
- 1.Skaper SD, Di Marzo V. Endocannabinoids in nervous system health and disease: The big picture in a nutshell. Philos. Trans. R. Soc. Lond. B. 2012;367:3193–3200. doi: 10.1098/rstb.2012.0313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003;83:1017–1066. doi: 10.1152/physrev.00004.2003. [DOI] [PubMed] [Google Scholar]
- 3.Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist. 2007;13:127–137. doi: 10.1177/1073858406296716. [DOI] [PubMed] [Google Scholar]
- 4.Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. Int. J. Mol. Sci. 2018;19:833. doi: 10.3390/ijms19030833. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ramaekers JG, et al. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31:2296–2303. doi: 10.1038/sj.npp.1301068. [DOI] [PubMed] [Google Scholar]
- 6.Hunault CC, et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC) Psychopharmacology. 2009;204:85–94. doi: 10.1007/s00213-008-1440-0. [DOI] [PubMed] [Google Scholar]
- 7.Bossong MG, Jager G, Bhattacharyya S, Allen P. Acute and non-acute effects of cannabis on human memory function: A critical review of neuroimaging studies. Curr. Pharm. Des. 2014;20:2114–2125. doi: 10.2174/13816128113199990436. [DOI] [PubMed] [Google Scholar]
- 8.Ramaekers JG, et al. Cannabis and tolerance: Acute drug impairment as a function of cannabis use history. Sci. Rep. 2016;6:26843. doi: 10.1038/srep26843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S. Effect of cannabis on glutamate signalling in the brain: A systematic review of human and animal evidence. Neurosci. Biobehav. Rev. 2016;64:359–381. doi: 10.1016/j.neubiorev.2016.03.010. [DOI] [PubMed] [Google Scholar]
- 10.Mason NL, et al. Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. Eur. Neuropsychopharmacol. 2019;29:247–256. doi: 10.1016/j.euroneuro.2018.12.003. [DOI] [PubMed] [Google Scholar]
- 11.Mason NL, et al. Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict. Biol. 2021;26:e12870. doi: 10.1111/adb.12870. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ramaekers JG, Mason NL, Theunissen EL. Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. Eur. Neuropsychopharmacol. 2020;36:191–205. doi: 10.1016/j.euroneuro.2020.01.006. [DOI] [PubMed] [Google Scholar]
- 13.Gorelick DA, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am. Heart J. 2006;151(754):e751–754. doi: 10.1016/j.ahj.2005.11.006. [DOI] [PubMed] [Google Scholar]
- 14.Huestis MA, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology. 2007;194:505–515. doi: 10.1007/s00213-007-0861-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zuurman L, et al. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J. Psychopharmacol. 2010;24:363–371. doi: 10.1177/0269881108096509. [DOI] [PubMed] [Google Scholar]
- 16.Englund A, et al. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial. J. Psychopharmacol. 2016;30:140–151. doi: 10.1177/0269881115615104. [DOI] [PubMed] [Google Scholar]
- 17.Pope HG, Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry. 2001;58:909–915. doi: 10.1001/archpsyc.58.10.909. [DOI] [PubMed] [Google Scholar]
- 18.Bosker WM, et al. Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PLoS ONE. 2013;8:e53127. doi: 10.1371/journal.pone.0053127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lorenzetti V, Solowij N, Yucel M. The role of cannabinoids in neuroanatomic alterations in cannabis users. Biol. Psychiatry. 2016;79:e17–31. doi: 10.1016/j.biopsych.2015.11.013. [DOI] [PubMed] [Google Scholar]
- 20.Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp. Clin. Psychopharmacol. 2012;20:420–429. doi: 10.1037/a0029117. [DOI] [PubMed] [Google Scholar]
- 21.Hirvonen J, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol. Psychiatry. 2012;17:642–649. doi: 10.1038/mp.2011.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ceccarini J, et al. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addict. Biol. 2015;20:357–367. doi: 10.1111/adb.12116. [DOI] [PubMed] [Google Scholar]
- 23.D'Souza DC, et al. Rapid Changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis. Biol. Psychiatry Cogn. Neurosci. Neuroimaging. 2016;1:60–67. doi: 10.1016/j.bpsc.2015.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mizrahi R, Watts JJ, Tseng KY. Mechanisms contributing to cognitive deficits in cannabis users. Neuropharmacology. 2017;124:84–88. doi: 10.1016/j.neuropharm.2017.04.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Friston KJ. Functional and effective connectivity: A review. Brain Connect. 2011;1:13–36. doi: 10.1089/brain.2011.0008. [DOI] [PubMed] [Google Scholar]
- 26.Battistella G, et al. Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PLoS ONE. 2013;8:e52545. doi: 10.1371/journal.pone.0052545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ramaekers JG, et al. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging Behav. 2016;10:1254–1263. doi: 10.1007/s11682-015-9488-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Bhattacharyya S, et al. Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry. 2012;69:27–36. doi: 10.1001/archgenpsychiatry.2011.161. [DOI] [PubMed] [Google Scholar]
- 29.Bhattacharyya S, et al. Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology. 2015;40:1343–1352. doi: 10.1038/npp.2014.258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Wall MB, et al. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. J. Psychopharmacol. 2019;33:822–830. doi: 10.1177/0269881119841568. [DOI] [PubMed] [Google Scholar]
- 31.Filbey FM, Dunlop J. Differential reward network functional connectivity in cannabis dependent and non-dependent users. Drug Alcohol Depend. 2014;140:101–111. doi: 10.1016/j.drugalcdep.2014.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Lichenstein SD, Musselman S, Shaw DS, Sitnick S, Forbes EE. Nucleus accumbens functional connectivity at age 20 is associated with trajectory of adolescent cannabis use and predicts psychosocial functioning in young adulthood. Addiction. 2017;112:1961–1970. doi: 10.1111/add.13882. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Pujol J, et al. Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users. J. Psychiatr. Res. 2014;51:68–78. doi: 10.1016/j.jpsychires.2013.12.008. [DOI] [PubMed] [Google Scholar]
- 34.Filbey F, Yezhuvath U. Functional connectivity in inhibitory control networks and severity of cannabis use disorder. Am. J. Drug Alcohol Abuse. 2013;39:382–391. doi: 10.3109/00952990.2013.841710. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Lopez-Larson MP, Rogowska J, Yurgelun-Todd D. Aberrant orbitofrontal connectivity in marijuana smoking adolescents. Dev. Cogn. Neurosci. 2015;16:54–62. doi: 10.1016/j.dcn.2015.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Subramaniam P, et al. Orbitofrontal connectivity is associated with depression and anxiety in marijuana-using adolescents. J. Affect. Disord. 2018;239:234–241. doi: 10.1016/j.jad.2018.07.002. [DOI] [PubMed] [Google Scholar]
- 37.Manza P, Tomasi D, Volkow ND. Subcortical local functional hyperconnectivity in cannabis dependence. Biol. Psychiatry Cogn. Neurosci. Neuroimaging. 2018;3:285–293. doi: 10.1016/j.bpsc.2017.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Ramaekers JG, Mason NL, Kloft L, Theunissen EL. The why behind the high: determinants of neurocognition during acute cannabis exposure. Nat. Rev. Neurosci. 2021;22:439–454. doi: 10.1038/s41583-021-00466-4. [DOI] [PubMed] [Google Scholar]
- 39.Zaytseva Y, et al. Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states. J. Psychopharmacol. 2019;33:811–821. doi: 10.1177/0269881119849814. [DOI] [PubMed] [Google Scholar]
- 40.Amico E, et al. Mapping the functional connectome traits of levels of consciousness. Neuroimage. 2017;148:201–211. doi: 10.1016/j.neuroimage.2017.01.020. [DOI] [PubMed] [Google Scholar]
- 41.Contreras JA, et al. Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered resting-state networks. Alzheimers Dement. 2017;6:40–49. doi: 10.1016/j.dadm.2016.12.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Amico E, et al. The disengaging brain: Dynamic transitions from cognitive engagement and alcoholism risk. Neuroimage. 2020;209:116515. doi: 10.1016/j.neuroimage.2020.116515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Amico E, Goni J. The quest for identifiability in human functional connectomes. Sci. Rep. 2018;8:8254. doi: 10.1038/s41598-018-25089-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Zalesky A, Fornito A, Bullmore ET. Network-based statistic: Identifying differences in brain networks. Neuroimage. 2010;53:1197–1207. doi: 10.1016/j.neuroimage.2010.06.041. [DOI] [PubMed] [Google Scholar]
- 45.Amico E, Arenas A, Goni J. Centralized and distributed cognitive task processing in the human connectome. Netw. Neurosci. 2019;3:455–474. doi: 10.1162/netn_a_00072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Dinges DP, Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav. Res. Methods Instrum. Comput. 1985;17:652–655. doi: 10.3758/BF03200977. [DOI] [Google Scholar]
- 47.Toennes SW, Hanisch S, Pogoda W, Wunder C, Paulke A. Pitfall in cannabinoid analysis–detection of a previously unrecognized interfering compound in human serum. Anal. Bioanal. Chem. 2015;407:463–470. doi: 10.1007/s00216-014-8301-y. [DOI] [PubMed] [Google Scholar]
- 48.Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012;59:2142–2154. doi: 10.1016/j.neuroimage.2011.10.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Power JD, et al. Methods to detect, characterize, and remove motion artifact in resting state fMRI. Neuroimage. 2014;84:320–341. doi: 10.1016/j.neuroimage.2013.08.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl. Neuroimage. 2012;62:782–790. doi: 10.1016/j.neuroimage.2011.09.015. [DOI] [PubMed] [Google Scholar]
- 51.Shen X, Tokoglu F, Papademetris X, Constable RT. Groupwise whole-brain parcellation from resting-state fMRI data for network node identification. Neuroimage. 2013;82:403–415. doi: 10.1016/j.neuroimage.2013.05.081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Yeo BT, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 2011;106:1125–1165. doi: 10.1152/jn.00338.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Bullmore ET, et al. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. IEEE Trans. Med. Imaging. 1999;18:32–42. doi: 10.1109/42.750253. [DOI] [PubMed] [Google Scholar]
- 54.Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: A primer with examples. Hum. Brain Mapp. 2002;15:1–25. doi: 10.1002/hbm.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Fornito A, Zalesky A, Bullmore E. Fundamentals of Brain Network Analysis. Academic Press; 2016. [Google Scholar]
- 56.Hyvarinen A. Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans. Neural Netw. 1999;10:626–634. doi: 10.1109/72.761722. [DOI] [PubMed] [Google Scholar]
- 57.Hyvarinen A, Oja E. Independent component analysis: Algorithms and applications. Neural Netw. 2000;13:411–430. doi: 10.1016/s0893-6080(00)00026-5. [DOI] [PubMed] [Google Scholar]
- 58.Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. Philos. Trans. A. 2016;374:20150202. doi: 10.1098/rsta.2015.0202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Särelä J, Vigário R. Overlearning in marginal distribution-based ICA: Analysis and solutions. J. Mach. Learn. Res. 2003;4:1447–1469. [Google Scholar]
- 60.Calhoun VD, et al. Method for multimodal analysis of independent source differences in schizophrenia: combining gray matter structural and auditory oddball functional data. Hum. Brain Mapp. 2006;27:47–62. doi: 10.1002/hbm.20166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Kessler D, Angstadt M, Welsh RC, Sripada C. Modality-spanning deficits in attention-deficit/hyperactivity disorder in functional networks, gray matter, and white matter. J. Neurosci. 2014;34:16555–16566. doi: 10.1523/JNEUROSCI.3156-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Calhoun VD, Liu J, Adali T. A review of group ICA for fMRI data and ICA for joint inference of imaging, genetic, and ERP data. Neuroimage. 2009;45:S163–172. doi: 10.1016/j.neuroimage.2008.10.057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J. Anal. Toxicol. 2008;32:470–477. doi: 10.1093/jat/32.7.470. [DOI] [PubMed] [Google Scholar]
- 64.Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat. Rev. Neurosci. 2002;3:201–215. doi: 10.1038/nrn755. [DOI] [PubMed] [Google Scholar]
- 65.Moreno-Rius J. The cerebellum, THC, and cannabis addiction: Findings from animal and human studies. Cerebellum. 2019;18:593–604. doi: 10.1007/s12311-018-0993-7. [DOI] [PubMed] [Google Scholar]
- 66.Raichle ME. The brain's default mode network. Annu. Rev. Neurosci. 2015;38:433–447. doi: 10.1146/annurev-neuro-071013-014030. [DOI] [PubMed] [Google Scholar]
- 67.WHO . The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research. WHO; 1993. [Google Scholar]
- 68.Sami MB, et al. Cannabis use linked to altered functional connectivity of the visual attentional connectivity in patients with psychosis and controls. Schizophr. Bull. Open. 2020;1:1–11. doi: 10.1093/schizbullopen/sgaa018. [DOI] [Google Scholar]
- 69.Van Waes V, Beverley JA, Siman H, Tseng KY, Steiner H. CB1 Cannabinoid receptor expression in the striatum: Association with corticostriatal circuits and developmental regulation. Front. Pharmacol. 2012;3:21. doi: 10.3389/fphar.2012.00021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Hillary FG, et al. Hyperconnectivity is a fundamental response to neurological disruption. Neuropsychology. 2015;29:59–75. doi: 10.1037/neu0000110. [DOI] [PubMed] [Google Scholar]
- 71.Bernier RA, et al. Dedifferentiation does not account for hyperconnectivity after traumatic brain injury. Front. Neurol. 2017;8:297. doi: 10.3389/fneur.2017.00297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Ersche KD, et al. Brain networks underlying vulnerability and resilience to drug addiction. Proc. Natl. Acad. Sci. USA. 2020;117:15253–15261. doi: 10.1073/pnas.2002509117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Menon V. Brain networks and cognitive impairment in psychiatric disorders. World Psychiatry. 2020;19:309–310. doi: 10.1002/wps.20799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Bressler SL, Menon V. Large-scale brain networks in cognition: emerging methods and principles. Trends Cogn. Sci. 2010;14:277–290. doi: 10.1016/j.tics.2010.04.004. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.